Methyl 3-(2-bromo-4-fluorophenyl)prop-2-enoate | 1246851-47-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: Methyl 3-(2-bromo-4-fluorophenyl)prop-2-enoate
• CAS: 1246851-47-7
• 化学式: C₁₀H₈BrFO₂
• 分子量: 259.075
• InChiKey: DKCTXBLIHSYOAP-UHFFFAOYSA-N

物化性质

• 沸点：
  302.1±27.0 °C(Predicted)
• 密度：
  1.516±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Methyl 3-(2-bromo-4-fluorophenyl)prop-2-enoate 在 5% Rh/C 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以99%的产率得到methyl 3-(2-bromo-4-fluorophenyl)propanoate
  参考文献：
  名称：

  PROSTAGLANDIN E RECEPTOR ANTAGONISTS

  摘要：

  本发明提供了由一般式I表示的前列腺素受体拮抗剂化合物，其中A、R、R1和R2如规范中所定义。

  公开号：

  US20100256385A1
• 作为产物：
  描述：

  2-溴-4-氟苯甲醛 、 甲氧羰基亚甲基三苯基正膦 以 四氢呋喃 为溶剂， 以97%的产率得到Methyl 3-(2-bromo-4-fluorophenyl)prop-2-enoate
  参考文献：
  名称：

  PROSTAGLANDIN E RECEPTOR ANTAGONISTS

  摘要：

  本发明提供了由一般式I表示的前列腺素受体拮抗剂化合物，其中A、R、R1和R2如规范中所定义。

  公开号：

  US20100256385A1

文献信息

• CYCLOPROPANAMINE COMPOUND AND USE THEREOF
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150266881A1

  公开（公告）日：2015-09-24

  The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R 1 , R 2 and R 3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R 1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R 2 and R 3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

  本发明提供一种具有赖氨酸特异性去甲基化酶1抑制作用的化合物，可用作预防或治疗精神分裂症、阿尔茨海默病、帕金森病或亨廷顿病等疾病的药物。本发明涉及一种由下式表示的化合物： 其中A是一个烃基，可选地具有取代基，或者是一个杂环基，可选地具有取代基；B是一个苯环，可选地具有进一步的取代基；R1、R2和R3分别是氢原子，或者是一个烃基，可选地具有取代基，或者是一个杂环基，可选地具有取代基；A和R1可选地结合在一起，与相邻的氮原子一起形成一个可选地具有取代基的环基；而R2和R3可选地结合在一起，与相邻的氮原子一起形成一个可选地具有取代基的环基，或其盐。
• Prostaglandin D2 antagonist
  申请人：Allergan, Inc.

  公开号：US20040162323A1

  公开（公告）日：2004-08-19

  Disclosed herein is compound 1 1 or a pharmaceutically acceptable salt, or a prodrug thereof. Compound 1 is useful for treating or preventing a variety of diseases or conditions. Results presented herein also demonstrate that Compound 1 is a prostaglandin D 2 antagonist, and as such is useful in the treatment or prevention of prostaglandin D 2 mediated conditions or diseases. A method comprising administering a prostaglandin D 2 antagonist to a mammal suffering from a disease or condition selected from the group consisting of the gastrointestinal tract disorders or diseases, hyperalgesia, allodynia, abdominal cramping, glaucoma, ocular hypertension, and ocular hypotension is also disclosed herein. Pharmaceutical compositions and products comprising compound 1 are also disclosed.

  本文披露了化合物11或其药学上可接受的盐或前药。化合物1可用于治疗或预防多种疾病或症状。本文还表明，化合物1是一种前列腺素D2拮抗剂，因此可用于治疗或预防前列腺素D2介导的疾病或症状。本文还披露了一种方法，包括向患有来自选组中的胃肠道紊乱或疾病、高痛觉、触觉过敏、腹部痉挛、青光眼、眼压高或眼压低的哺乳动物施用前列腺素D2拮抗剂。本文还披露了包含化合物1的制药组合物和产品。
• Prostaglandin EP4 antagonist
  申请人：Woodward David

  公开号：US20050065200A1

  公开（公告）日：2005-03-24

  Disclosed herein are methods and compositions related to compound 1 or a pharmaceutically acceptable salt, or a prodrug thereof (all of which are referred to hereafter, collectively or individually, as “compound 1”), which is an antagonist of a prostaglandin EP 4 receptor, or is a prostaglandin EP 4 antagonist. Also disclosed is a method comprising administering a prostaglandin EP 4 antagonist to a mammal suffering from, or at risk of developing, a disease or condition selected from the group consisting of cancer, immunological disorders, neurodegenerative disorders, ocular diseases, hepatic diseases, renal diseases, septicemia, fibromyalgia, dermatological disorders, and antipyrexia.

  本文披露了与化合物1或其药物可接受盐或前药（以下统称为“化合物1”）相关的方法和组合物，该化合物是前列腺素EP4受体的拮抗剂或前列腺素EP4拮抗剂。还披露了一种方法，包括向患有或有发展成癌症、免疫障碍、神经退行性疾病、眼部疾病、肝脏疾病、肾脏疾病、败血症、纤维肌痛、皮肤病和退热症的哺乳动物施用前列腺素EP4拮抗剂。
• Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists
  申请人：——

  公开号：US20020128233A1

  公开（公告）日：2002-09-12

  The present invention provides novel compounds represented by the general 1 wherein m, n, X, Y, Z, R, R 1 and R 2 are as defined in the specification or a pharmaceutically acceptable salt thereof. The novel compounds are PGF 2&agr; antagonists, useful in pharmaceutical compositions for treating PGF 2&agr; -mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.

  本发明提供了由通式1表示的新化合物，其中m，n，X，Y，Z，R，R1和R2如规范中定义或其药学上可接受的盐。这些新化合物是PGF2α拮抗剂，可用于制备药物组合物，用于治疗PGF2α介导的疾病反应，如与类风湿性关节炎和牛皮癣有关的炎症反应，生殖障碍，支气管收缩性疾病（哮喘），过度骨质破坏（骨质疏松症），消化性溃疡，心脏病，血小板聚集和血栓形成。
• Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
  申请人：ALLERGAN SALES, INC.

  公开号：US20020165399A1

  公开（公告）日：2002-11-07

  The present invention provides novel compounds represented by the general formula I. 1 and pharmaceutically acceptable salts thereof wherein m, n, X, R, R 1 and R 2 are as defined in the specification. The novel compounds are PGF 2&agr; antagonists, useful in pharmaceutical compositions for treating PGF 2&agr; -mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.

  本发明提供了通式 I 所代表的新型化合物。 1 及其药学上可接受的盐类 其中 m、n、X、R、R 1 和 R 2 如说明书中所定义。新型化合物是 PGF 2&agr； 拮抗剂，可用于治疗 PGF 2&agr； -介导的疾病反应，如类风湿性关节炎和牛皮癣的炎症反应、生殖系统疾病、支气管收缩性疾病（哮喘）、骨质过度分解（骨质疏松症）、消化性溃疡、心脏病、血小板聚集和血栓形成。